Cargando…
Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2
INTRODUCTION: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). AIM: The aim of this study is to anal...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341519/ https://www.ncbi.nlm.nih.gov/pubmed/35923829 http://dx.doi.org/10.3389/fneur.2022.932883 |
_version_ | 1784760625496326144 |
---|---|
author | Peric, Stojan Zlatar, Jelena Nikolic, Luka Ivanovic, Vukan Pesovic, Jovan Petrovic Djordjevic, Ivana Sreckovic, Svetlana Savic-Pavicevic, Dusanka Meola, Giovanni Rakocevic-Stojanovic, Vidosava |
author_facet | Peric, Stojan Zlatar, Jelena Nikolic, Luka Ivanovic, Vukan Pesovic, Jovan Petrovic Djordjevic, Ivana Sreckovic, Svetlana Savic-Pavicevic, Dusanka Meola, Giovanni Rakocevic-Stojanovic, Vidosava |
author_sort | Peric, Stojan |
collection | PubMed |
description | INTRODUCTION: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). AIM: The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. PATIENTS AND METHODS: A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. RESULTS: Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, p <0.01). CONCLUSION: AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2. |
format | Online Article Text |
id | pubmed-9341519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93415192022-08-02 Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2 Peric, Stojan Zlatar, Jelena Nikolic, Luka Ivanovic, Vukan Pesovic, Jovan Petrovic Djordjevic, Ivana Sreckovic, Svetlana Savic-Pavicevic, Dusanka Meola, Giovanni Rakocevic-Stojanovic, Vidosava Front Neurol Neurology INTRODUCTION: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). AIM: The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. PATIENTS AND METHODS: A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. RESULTS: Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, p <0.01). CONCLUSION: AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2. Frontiers Media S.A. 2022-07-18 /pmc/articles/PMC9341519/ /pubmed/35923829 http://dx.doi.org/10.3389/fneur.2022.932883 Text en Copyright © 2022 Peric, Zlatar, Nikolic, Ivanovic, Pesovic, Petrovic Djordjevic, Sreckovic, Savic-Pavicevic, Meola and Rakocevic-Stojanovic. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Peric, Stojan Zlatar, Jelena Nikolic, Luka Ivanovic, Vukan Pesovic, Jovan Petrovic Djordjevic, Ivana Sreckovic, Svetlana Savic-Pavicevic, Dusanka Meola, Giovanni Rakocevic-Stojanovic, Vidosava Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2 |
title | Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2 |
title_full | Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2 |
title_fullStr | Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2 |
title_full_unstemmed | Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2 |
title_short | Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2 |
title_sort | autoimmune diseases in patients with myotonic dystrophy type 2 |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9341519/ https://www.ncbi.nlm.nih.gov/pubmed/35923829 http://dx.doi.org/10.3389/fneur.2022.932883 |
work_keys_str_mv | AT pericstojan autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT zlatarjelena autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT nikolicluka autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT ivanovicvukan autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT pesovicjovan autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT petrovicdjordjevicivana autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT sreckovicsvetlana autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT savicpavicevicdusanka autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT meolagiovanni autoimmunediseasesinpatientswithmyotonicdystrophytype2 AT rakocevicstojanovicvidosava autoimmunediseasesinpatientswithmyotonicdystrophytype2 |